4Filed Jun 23, 8:00 PM ET

Evommune (EVMN) CSO Jeegar Patel Exercises Options, Sells Shares

$EVMN · Evommune, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Evommune (EVMN) CSO Jeegar Patel Exercises Options, Sells Shares

What Happened
Jeegar Patel, Chief Scientific Officer of Evommune (EVMN), exercised 1,488 stock options at $3.84 per share (cost $5,714) and sold those 1,488 shares in the open market at $22.50 per share for gross proceeds of $33,480 on 2026-06-22. The filing also shows a related derivative disposition recorded at $0.00 (see Key Details). The transactions were executed under a Rule 10b5-1 trading plan.

Key Details

  • Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (appears timely).
  • Exercise: 1,488 shares (code M) acquired at $3.84 each — total exercise cost $5,714.
  • Sale: 1,488 shares (code S) sold at $22.50 each — total proceeds $33,480.
  • Net proceeds (sale minus exercise cost): $33,480 − $5,714 = $27,766 (before taxes/fees).
  • Derivative entry: 1,488 shares reported disposed at $0.00 — often used to report shares withheld/surrendered in connection with exercise or tax obligations.
  • Shares owned after the transactions: not specified in the provided filing excerpt.
  • Footnotes: F1 — transactions were pursuant to a Rule 10b5-1 plan adopted Feb 27, 2026; F2 — option vesting schedule (1/4 after one year, then monthly over 36 months).
  • Transaction codes: M = option exercise/conversion, S = sale.

Context
Because the shares were exercised and then sold the same day, this effectively functions as a cashless exercise + immediate sale (routine monetization). Sales by insiders are common and do not by themselves indicate a change in company outlook; purchases tend to be more informative for bullish signals. The $0.00 derivative disposition typically reflects withholding or surrender of shares to cover taxes or option-related costs.